Sarasota, FL -- (SBWire) -- 07/26/2018 --Zion Market Research has published a new report titled "Hepatitis C Drug Market for Hospitals, Private labs, Physician offices, Public health labs and Blood banks - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022." According to the report, the global Hepatitis C drug market accounted for around USD 13.50 billion in 2016 and is expected to reach approximately USD 33.50 by 2022, growing at a CAGR of around 16.0% between 2017 and 2022.
Request Free Sample Report @ https://bit.ly/2JSECI0
Hepatitis C virus is a small (55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that a minimum of 3 percent of the world's population is chronically infected with HCV. HCV is most commonly spread by direct contact with infected blood and blood products. Availability of injectable therapies and drugs has had a remarkable influence on HCV epidemiology. The incubation period of HCV, though ranging up to several months, averages 6-8 weeks.
The report covers forecast and analysis for the Hepatitis C drug market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD Billion). The study includes drivers and restraints for the Hepatitis C drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Hepatitis C drug market on a global level.
Download Research Report Brochure @ https://bit.ly/2AaR5qR
This report offers comprehensive coverage on global Hepatitis C drug market along with, market trends, drivers, and restraints of Hepatitis C drug market. This report included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter's five forces model for the Hepatitis C drug market has also been included. The study encompasses a market attractiveness analysis, wherein each segment are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared using data sourced from in-house databases, secondary and primary research team of industry experts.
In terms of geography, North America was the leading market for hepatitis C drug market in 2016 in terms of revenue due to the wide availability of hospitals. Furthermore, lifestyle-related factors such as having multiple sex partners, unprotected sex has become very common in North America and European countries. Moreover, hepatitis C drug has huge opportunity in emerging market like Asia Pacific and Latin America due to the increasing number of HCV patient, government initiatives, and healthcare infrastructure.
Inquiry more about this report @ https://bit.ly/2LmECWe
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global hepatitis C drug market including Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.
Hepatitis C Drug Market Reflecting a CAGR of 16.0% by 2022
Global Hepatitis C Drug Market is Set for a Rapid Growth and is Expected to Reach around USD 33.50 Billion by 2022